Notably, two of the identified clinical tier I–II variants were found more than once in two different patients: KRAS p.G12D (2 PDAC) and KRAS p.G12V (1 CCA, 1 IPMN). Here, KRAS is linked to pancreatic intraductal papillary-mucinous neoplasm.